Cargando…

NDRG3 regulates imatinib resistance by promoting β‑catenin accumulation in the nucleus in chronic myelogenous leukemia

Imatinib resistance in chronic myelogenous leukemia (CML) is a clinical problem. The present study examined the role of N-Myc downstream regulatory gene 3 (NDRG3) in imatinib resistance in CML. Quantitative PCR demonstrated that NDRG3 was highly expressed in patients with CML. Cell Counting Kit (CCK...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xiao, Rong, Simin, Sun, Yunxiao, Yin, Baohui, Yang, Xiancong, Lu, Xiaoqing, Sun, Hongfang, Yan, Yunfei, Sun, Guangbin, Liang, Yan, Wang, Pingyu, Xie, Shuyang, Li, Youjie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308491/ https://www.ncbi.nlm.nih.gov/pubmed/37350410 http://dx.doi.org/10.3892/or.2023.8589

Ejemplares similares

TRIB2 regulates the expression of miR-33a-5p through the ERK/c-Fos pathway to affect the imatinib resistance of chronic myeloid leukemia cells
por: Sun, Hang, et al.
Publicado: (2022)

MiR‐138‐5p suppresses the progression of lung cancer by targeting SNIP1
por: Wu, Jiaen, et al.
Publicado: (2023)

Gene SH3BGRL3 regulates acute myeloid leukemia progression through circRNA_0010984 based on competitive endogenous RNA mechanism
por: Yang, Xiancong, et al.
Publicado: (2023)

Anticancer roles of let-7f-1-3p in non-small cell lung cancer via direct targeting of integrin β1
por: Yang, Yanan, et al.
Publicado: (2021)

Progress of research on PD-1/PD-L1 in leukemia
por: Cao, Huizhen, et al.
Publicado: (2023)

The treatment of pediatric chronic myelogenous leukemia in the imatinib era
por: Lee, Jae Wook, et al.
Publicado: (2011)

Imatinib Therapy in Chronic Myelogenous Leukemia and Thyroid Function Tests
por: Mashhadi, Mohammad Ali, et al.
Publicado: (2014)

HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation
por: Kim, Soo Jung, et al.
Publicado: (2014)

Translocation of heme oxygenase-1 contributes to imatinib resistance in chronic myelogenous leukemia
por: Schaefer, Bianca, et al.
Publicado: (2017)

Homoharringtonine enhances the effect of imatinib on chronic myelogenous leukemia cells by downregulating ZFX
por: Wu, Jingjing, et al.
Publicado: (2019)

High NDRG3 expression facilitates HCC metastasis by promoting nuclear translocation of β-catenin
por: Shi, JiKui, et al.
Publicado: (2019)

Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia
por: Oh, Hyun Jin, et al.
Publicado: (2013)

Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells
por: Peng, Xing-Xiang, et al.
Publicado: (2012)

Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia
por: Shea, Lauren K., et al.
Publicado: (2017)

Mesenchymal soluble factors confer imatinib drug resistance in chronic myelogenous leukemia cells
por: Regev, Ofer, et al.
Publicado: (2020)

Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells
por: Prado-Carrillo, Omar, et al.
Publicado: (2022)

Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case report
por: Shimabukuro-Vornhagen, Alexander, et al.
Publicado: (2011)

Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib?
por: Martinelli, Giovanni, et al.
Publicado: (2009)

Familial congenital cyanosis caused by Hb-M(Yantai)(α-76 GAC → TAC, Asp → Tyr)
por: Sun, Yanbo, et al.
Publicado: (2010)

NDRG2 expression decreases with tumor stages and regulates TCF/β-catenin signaling in human colon carcinoma
por: Kim, Young-Jun, et al.
Publicado: (2009)

Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning
por: Topaly, J, et al.
Publicado: (2002)

Aberrant DNA Methylation Is Associated with Disease Progression, Resistance to Imatinib and Shortened Survival in Chronic Myelogenous Leukemia
por: Jelinek, Jaroslav, et al.
Publicado: (2011)

Real-Time Analysis of Imatinib- and Dasatinib-Induced Effects on Chronic Myelogenous Leukemia Cell Interaction with Fibronectin
por: Obr, Adam, et al.
Publicado: (2014)

Coordinate Modulation of Glycolytic Enzymes and OXPHOS by Imatinib in BCR-ABL Driven Chronic Myelogenous Leukemia Cells
por: De Rosa, Viviana, et al.
Publicado: (2019)

High expression of NDRG3 in osteoarthritis patients
por: Chen, Long, et al.
Publicado: (2021)

Increased financial burden among patients with chronic myelogenous leukaemia receiving imatinib in Japan: a retrospective survey
por: Kodama, Yuko, et al.
Publicado: (2012)

Correction: Real-Time Analysis of Imatinib- and Dasatinib-Induced Effects on Chronic Myelogenous Leukemia Cell Interaction with Fibronectin
Publicado: (2014)

High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients
por: Delord, Marc, et al.
Publicado: (2013)

The metastasis suppressor, NDRG1, inhibits “stemness” of colorectal cancer via down-regulation of nuclear β-catenin and CD44
por: Wangpu, Xiongzhi, et al.
Publicado: (2015)

A Novel Aging-Related Prognostic lncRNA Signature Correlated with Immune Cell Infiltration and Response to Immunotherapy in Breast Cancer
por: Liu, Zhixin, et al.
Publicado: (2023)

Characterization of the prognostic values of the NDRG family in gastric cancer
por: Yu, Chaoran, et al.
Publicado: (2019)

NDRG1 suppresses vasculogenic mimicry and tumor aggressiveness in gastric carcinoma
por: Dong, Xueyi, et al.
Publicado: (2019)

ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia
por: Perrotti, D, et al.
Publicado: (2006)

A Case of Isolated Lymphoblastic Relapse of the Central Nervous System in a Patient with Chronic Myelogenous Leukemia Treated with Imatinib
por: Park, Mi-Jung, et al.
Publicado: (2014)

Altered intracellular signaling by imatinib increases the anti‐cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells
por: Hirao, Takuya, et al.
Publicado: (2017)

A novel case of chronic spontaneous urticaria associated chronic myelogenous leukemia with rapid resolution upon treatment with imatinib
por: Tracy, Alexis, et al.
Publicado: (2022)

Imatinib-Induced Psoriasis
por: Atalay, Figen, et al.
Publicado: (2013)

NDRG1 is expressed in human granulosa cells: An implicative role of NDRG1 in the ovary
por: Nishigaki, Akemi, et al.
Publicado: (2022)

Clinical Diagnostic and Prognostic Potential of NDRG1 and NDRG2 in Hepatocellular Carcinoma Patients
por: Xu, Shaohua, et al.
Publicado: (2022)

Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib Treatments
por: Xu, Lianrong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_iqcnpr5md9hmutgga9b85onae0